Vectura Group announces Chief Executive's intention to step down

Chippenham, UK - 3 February 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") announces today that after twelve years with Vectura, Dr Chris Blackwell, Chief Executive, has informed the Board of his intention to step down as Chief Executive.  Chris joined Vectura before the Initial Public Offering (IPO) and has led the Company to its current position as a publicly listed company and a leader in the treatment of airways diseases.  Chris will remain in his role until the end of June 2015 and will assist the Board with the search for his successor.

Dr Chris Blackwell, Chief Executive:
"I am intensely proud of what we have achieved over the past twelve years and I feel that now is the right time to move on.  I remain totally focused on the continued evolution of Vectura and I am confident that the business is in great shape, with the right senior management team to ensure that the Company continues to thrive."

"I would also like to take this opportunity to express my gratitude to those, past and present, who have helped build the Company, to those who have supported its growth and to the Board for their understanding and support."

Bruno Angelici, Chairman:
"I have enjoyed working with Chris and I warmly thank him for the great results achieved under his leadership.  Whilst we will be sad to see Chris depart, he will leave the business in a very strong position.  On behalf of the entire Board I would like to wish him well in his future endeavours."

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.